Abstract
Acetylcholinesterase inhibitors are regarded as the most promising approach to treat Alzheimer’s disease (AD). However, their anticipated side effects limit their usage. Present investigations involved the incorporation of the newly synthesized 2-naphthol derivatives (PP-81 and PP-84) into solid lipid nanoparticles (SLNs) to improve their accessibility to the brain and enhance the levels of acetylcholine. Drug loaded SLNs of PP-81 and PP-84 showed that average particle size of 138 nm and 186 nm, positive zeta potential and total drug content of 86.13 ± 0.49 % w/v and 81.18 ± 0.78 % w/v respectively were obtained using microemulsification technique. The particles were found to be spherical in shape, with high drug entrapment (91.28 ± 0.14 % w/w, PP-81 and 70.94 ± 0.59 % w/w, PP-84) at 10 % drug loading. Confirmation of SLNs formation was performed using DSC and PXRD studies. In in vitro release study diffusion phenomenon was predominant and was prolonged up to 24 h. Elevated plus maze test was carried out to evaluate memory acquisition and retention; post treatment with SLNs and respective free drugs in scopolamine induced spatial memory deficit in mice. Results indicated a significant increase (p < 0.05) in percentage retention of memory and learning with PP-81 and PP- 84 SLNs respectively at 20 mg/kg. It can be an optimized potential therapeutic and brain targeting approach for the treatment of AD.
Keywords: Alzheimer’s disease, acetylcholinesterase inhibitors, microemulsification method, solid lipid nanoparticles, DSC, PXRD, elevated plus maze.
Current Drug Therapy
Title:Newly Synthesized Acetylcholinesterase Inhibitors for Alleviating Alzheimer’s Disease using Solid Lipid Nanoparticles
Volume: 9 Issue: 2
Author(s): Rohit Makkar, Paramveer Singh, Chhanda C. Danta, Vandita Kakkar, Indu P. Kaur and Poonam Piplani
Affiliation:
Keywords: Alzheimer’s disease, acetylcholinesterase inhibitors, microemulsification method, solid lipid nanoparticles, DSC, PXRD, elevated plus maze.
Abstract: Acetylcholinesterase inhibitors are regarded as the most promising approach to treat Alzheimer’s disease (AD). However, their anticipated side effects limit their usage. Present investigations involved the incorporation of the newly synthesized 2-naphthol derivatives (PP-81 and PP-84) into solid lipid nanoparticles (SLNs) to improve their accessibility to the brain and enhance the levels of acetylcholine. Drug loaded SLNs of PP-81 and PP-84 showed that average particle size of 138 nm and 186 nm, positive zeta potential and total drug content of 86.13 ± 0.49 % w/v and 81.18 ± 0.78 % w/v respectively were obtained using microemulsification technique. The particles were found to be spherical in shape, with high drug entrapment (91.28 ± 0.14 % w/w, PP-81 and 70.94 ± 0.59 % w/w, PP-84) at 10 % drug loading. Confirmation of SLNs formation was performed using DSC and PXRD studies. In in vitro release study diffusion phenomenon was predominant and was prolonged up to 24 h. Elevated plus maze test was carried out to evaluate memory acquisition and retention; post treatment with SLNs and respective free drugs in scopolamine induced spatial memory deficit in mice. Results indicated a significant increase (p < 0.05) in percentage retention of memory and learning with PP-81 and PP- 84 SLNs respectively at 20 mg/kg. It can be an optimized potential therapeutic and brain targeting approach for the treatment of AD.
Export Options
About this article
Cite this article as:
Makkar Rohit, Singh Paramveer, C. Danta Chhanda, Kakkar Vandita, P. Kaur Indu and Piplani Poonam, Newly Synthesized Acetylcholinesterase Inhibitors for Alleviating Alzheimer’s Disease using Solid Lipid Nanoparticles, Current Drug Therapy 2014; 9 (2) . https://dx.doi.org/10.2174/1574885509666140804222101
DOI https://dx.doi.org/10.2174/1574885509666140804222101 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Discovery in Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Comparison of Novel Tacrine and 7-MEOTA Derivatives with Aromatic and Alicyclic Residues: Synthesis, Biological Evaluation and Docking Studies
Letters in Organic Chemistry How Valid is Placebo in the Indian Setting?
Central Nervous System Agents in Medicinal Chemistry New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Nanosuspension Technology: A Strategic Approach for Poorly Soluble Drugs
Nanoscience & Nanotechnology-Asia The Role of CXCR3 in Neurological Diseases
Current Neuropharmacology Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: A Review
Current Drug Therapy Probable Novel PSEN1 Gln222Leu Mutation in a Chinese Family with Early-Onset Alzheimer's Disease
Current Alzheimer Research Characterizing the Binding of Angiotensin Converting Enzyme I Inhibitory Peptide to Human Hemoglobin: Influence of Electromagnetic Fields
Protein & Peptide Letters The role of vitamin D towards immune tolerance in white adipose tissue (WAT)
Endocrine, Metabolic & Immune Disorders - Drug Targets Executive Dyscontrol in Dementia, with Emphasis on Subcortical Pathology and the Role of Butyrylcholinesterase
Current Alzheimer Research INTRODUCTORY CONSIDERATIONS Athanasios Koukopoulos: The Man, the Psychiatrist, the Original Thinker
Current Neuropharmacology Alzheimer’s Disease-like Early-phase Brain Pathogenesis: Self-curing Amelioration of Neurodegeneration from Pro-inflammatory ‘Wounding’ to Anti-inflammatory ‘Healing’
Current Alzheimer Research Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma
Current Neuropharmacology Emerging Vascular Risk Factors in Women: Any Differences from Men?
Current Medicinal Chemistry The Potential Role of the Endocannabinoid System in the Control of Multiple Scleorsis
Current Medicinal Chemistry - Central Nervous System Agents Author Index To Volume 5
CNS & Neurological Disorders - Drug Targets Biological Characteristics and Role of Histamine in Case of Allergic Rhinitis
Medicinal Chemistry Reviews - Online (Discontinued) Ginsenoside Rg1 Attenuates Oligomeric Aβ1-42-Induced Mitochondrial Dysfunction
Current Alzheimer Research Editorial [Hot Topic: Alzheimer Drug Design Based on the Amyloid Hypothesis (Executive Editors: D. Munoz-Torrero and P. Camps)]
Current Pharmaceutical Design